Certara Inc
$ 6.59
-1.49%
25 Feb - close price
- Market Cap 1,049,611,000 USD
- Current Price $ 6.59
- High / Low $ 6.75 / 6.46
- Stock P/E 94.14
- Book Value 6.68
- EPS 0.07
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.01 %
- 52 Week High 15.38
- 52 Week Low 6.32
About
Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$12.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-02-26 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-02-29 | 2023-11-08 | 2023-08-09 | 2023-05-08 |
| Reported EPS | 0 | 0.14 | 0.07 | 0.0294 | 0.15 | 0.13 | 0.07 | 0.1 | 0.09 | 0.11 | 0.12 | 0.12 |
| Estimated EPS | 0.1129 | 0.1099 | 0.1 | 0.1134 | 0.1254 | 0.11 | 0.1 | 0.1 | 0.11 | 0.11 | 0.13 | 0.12 |
| Surprise | -0.1129 | 0.0301 | -0.03 | -0.084 | 0.0246 | 0.02 | -0.03 | 0 | -0.02 | 0 | -0.01 | 0 |
| Surprise Percentage | -100% | 27.3885% | -30% | -74.0741% | 19.6172% | 18.1818% | -30% | 0% | -18.1818% | 0% | -7.6923% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERT
2026-02-26 11:52:37
Certara, Inc. released its annual Form 10-K report, highlighting a 9% increase in total revenues to $418.8 million and a significant improvement in income from operations to $21.0 million. The company, a leader in biosimulation and AI integration for drug development, expanded its product portfolio and customer base globally. Certara plans future growth through acquisitions, AI investments, and disciplined capital management, while navigating regulatory challenges, technological innovation demands, and market competition.
2026-02-26 11:52:37
Certara, Inc., a leader in model-informed drug development, announced its financial results for Q4 and the full fiscal year 2025. The company reported a 3% Q4 revenue growth to $103.6 million, but a net loss of $5.9 million, down from a net income of $6.6 million in the prior year. For the full year, revenue grew 9% to $418.8 million, with adjusted EBITDA up 10% to $134.5 million, and it outlined strategic initiatives for 2026, including leadership changes and projected revenue growth of 0-4%.
2026-02-26 10:52:38
Certara, Inc. reported its fourth quarter and full fiscal year 2025 financial results, with FY 2025 revenue at $418.8 million (9% growth) and Adjusted EBITDA at $134.5 million (10% growth). The company provided guidance for full year 2026, expecting revenue growth of 0-4%, an Adjusted EBITDA margin of 30-32%, and adjusted diluted EPS of $0.44-$0.48. Jon Resnick was appointed CEO, effective January 1st, 2026, and highlighted plans for strategic focus and innovation to drive future growth.
2026-02-25 19:52:38
Certara's stock has plunged following a disappointing earnings report, which revealed decelerated growth and a 3% dip in adjusted EBITDA. This downturn comes as new CEO Jon Resnick takes the helm and the company introduces its AI-driven Certara IQ platform, aiming to revolutionize drug development. Despite the near-term challenges and pessimistic market reaction, the article suggests that Certara IQ and new leadership could drive a future turnaround, making current valuations appear inexpensive for a high-risk, high-reward investment.
2026-02-25 17:52:38
Certara (CERT) is scheduled to release its Q4 earnings on February 26 before market open. Analysts anticipate an EPS of $0.10, a year-over-year decline of 33.3%, and revenue of $103.23 million, representing a modest 2.8% growth. The company has a history of consistently beating EPS and revenue estimates and recently appointed Jon Resnick as CEO, reaffirming its FY25 outlook.
2026-02-25 06:53:35
Analysts are providing mixed ratings for several healthcare companies. Henry Schein (HSIC) received a Hold rating from William Blair, while Delcath Systems (DCTH) and Certara (CERT) both maintained Buy ratings from Craig-Hallum, with significant upside potential noted for Delcath Systems. The report highlights individual analyst performance and consensus price targets for each stock in the Healthcare sector.
